Literature DB >> 12748350

Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis.

Goce B Spasovski1, An R J Bervoets, Geert J S Behets, Ninoslav Ivanovski, Aleksander Sikole, Geert Dams, Marie-M Couttenye, Marc E De Broe, Patrick C D'Haese.   

Abstract

BACKGROUND: During the last few years the spectrum of renal osteodystrophy (ROD) in dialysis patients has been studied thoroughly and the prevalence of the various types of ROD has changed considerably. Whereas until a decade ago most patients presented with secondary hyperparathyroidism (HPTH), adynamic bone (ABD) has become the most common lesion within the dialysis population over the last few years. Much less is known about the spectrum of ROD in end-stage renal failure (ESRF) patients not yet on dialysis.
METHODS: Transiliac bone biopsies were taken in an unselected group of 84 ESRF patients (44 male, age 54+/-12 years) before enrolment in a dialysis programme. All patients were recruited within a time period of 10 months from various centres (n=18) in Macedonia. Calcium carbonate was the only prescribed medication in patients followed up by the outpatient clinic.
RESULTS: HPTH was found in only 9% of the patients, whilst ABD appeared to be the most frequent renal bone disease as it was observed in 23% of the cases next to normal bone (38%). A relatively high number of patients (n=10; 12%) fulfilled the criteria of osteomalacia (OM). Mixed osteodystrophy (MX) was diagnosed in 18% of the subjects. There was no significant difference between groups in age, creatinine, or serum and bone strontium and aluminium levels. Patient characteristics associated with ABD included male gender and diabetes, whilst OM was associated with older age (>58 years).
CONCLUSIONS: In an unselected population of ESRF patients already, 62% of them have an abnormal bone histology. ABD is the most prevalent type of ROD in this population. In the absence of aluminium or strontium accumulation the relatively high prevalence of a low bone turnover as expressed by either normal bone or ABD and OM is striking.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12748350     DOI: 10.1093/ndt/gfg116

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  32 in total

1.  The increasing number of older patients with renal disease.

Authors:  R J A Sims; M J D Cassidy; T Masud
Journal:  BMJ       Date:  2003-08-30

2.  Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure.

Authors:  Michael P Whyte; Rattana Leelawattana; William R Reinus; Chang Yang; Steven Mumm; Deborah V Novack
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

3.  Inflammation and the bone-vascular axis in end-stage renal disease.

Authors:  L Viaene; G J Behets; S Heye; K Claes; D Monbaliu; J Pirenne; P C D'Haese; P Evenepoel
Journal:  Osteoporos Int       Date:  2015-08-21       Impact factor: 4.507

Review 4.  Update on the role of bone biopsy in the management of patients with CKD-MBD.

Authors:  P Evenepoel; G J S Behets; M R Laurent; P C D'Haese
Journal:  J Nephrol       Date:  2017-08-22       Impact factor: 3.902

5.  Calcium and phosphate balance in adolescents on home nocturnal haemodialysis.

Authors:  Daljit K Hothi; Elizabeth Harvey; Elizabeth Piva; Laura Keating; Donna Secker; Denis F Geary
Journal:  Pediatr Nephrol       Date:  2006-04-01       Impact factor: 3.714

Review 6.  Updates in CKD-Associated Osteoporosis.

Authors:  Pascale Khairallah; Thomas L Nickolas
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 7.  Role of bone biopsy in stages 3 to 4 chronic kidney disease.

Authors:  Anca Gal-Moscovici; Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

Review 8.  Bone health and vascular calcification relationships in chronic kidney disease.

Authors:  Goce B Spasovski
Journal:  Int Urol Nephrol       Date:  2007-09-26       Impact factor: 2.370

9.  Vitamin D receptor activators can protect against vascular calcification.

Authors:  Suresh Mathew; Richard J Lund; Lala R Chaudhary; Theresa Geurs; Keith A Hruska
Journal:  J Am Soc Nephrol       Date:  2008-04-30       Impact factor: 10.121

10.  The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.

Authors:  Piergiorgio Messa; Fernando Macário; Magdi Yaqoob; Koen Bouman; Johann Braun; Beat von Albertini; Hans Brink; Francisco Maduell; Helmut Graf; João M Frazão; Willem Jan Bos; Vicente Torregrosa; Heikki Saha; Helmut Reichel; Martin Wilkie; Valter J Zani; Bart Molemans; Dave Carter; Francesco Locatelli
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.